Replimune Group Inc (REPL)
Healthcare
Biotechnology
11.90 $
+6.3%
vs. previous close
Closing price · As of: 3. Aug 2026
Replimune Group Inc (REPL) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2026), "Operating Cash Flow" came in at -280 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| -7.1 | -16 | -25 | -61 | -61 | -82 | -128 | -185 | -192 | -280 | |
| 0.1 | 0.1 | 0.1 | 0.5 | 1.7 | 2.1 | 2.4 | 2.7 | 3.5 | 4.1 | |
| 0.2 | 0.8 | 2.7 | 7.7 | 12 | 24 | 28 | 34 | 35 | 32 | |
| 0.4 | 1.7 | 8.3 | 7.9 | 13 | 26 | – | – | – | – | |
| 0.1 | 1.9 | -1.3 | -15 | 3.5 | 7.2 | 15 | 5.5 | 24 | -3.8 | |
| 0.2 | 0.1 | 2.6 | 6.5 | 2.4 | 2.3 | 2.3 | 5.7 | 6.7 | 4.2 | |
| -0.2 | -44 | -66 | -5.2 | -189 | -1.8 | -143 | 97 | -24 | 311 | |
| – | – | – | 28 | 92 | – | – | – | – | – | |
| 15 | 55 | 101 | 28 | 92 | – | 93 | – | – | – | |
| 9.9 | 9.9 | 9.9 | 10 | -11 | -0.3 | 28 | 15 | -0.6 | 34 | |
| 15 | 55 | 101 | 100 | 372 | 6.6 | 311 | 16 | 252 | 66 | |
| 6.3 | -3.0 | 9.2 | 34 | 123 | -77 | 41 | -72 | 37 | 98 | |
| -7.3 | -16 | -28 | -67 | -64 | -85 | -130 | -191 | -199 | -285 |
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.